{"altmetric_id":104178,"counts":{"readers":{"mendeley":65,"citeulike":0,"connotea":0},"blogs":{"unique_users_count":2,"unique_users":[1234,1179],"posts_count":2},"news":{"unique_users_count":2,"unique_users":["oncology_nurse_advisor","the_asco_post"],"posts_count":3},"total":{"posts_count":11},"f1000":{"unique_users_count":1,"unique_users":["F1000Prime"],"posts_count":2},"twitter":{"unique_users_count":3,"unique_users":["HUMBLETIsabelle","aftimosp","cordekroon"],"posts_count":3},"wikipedia":{"unique_users_count":1,"unique_users":["en:24370009"],"posts_count":1}},"selected_quotes":["@BRSTKNKRactie Blijkt 56-34% clinical benefit te zijn. Oproep v echte uitkomsten! Mediane overleving: 7.7 vs 12.2 mnd"],"citation":{"abstract":"Triple-negative breast cancers have inherent defects in DNA repair, making this cancer a rational target for therapy based on poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition.","abstract_source":"pubmed","altmetric_jid":"4f6fa50e3cf058f6100031c4","authors":["Joyce O'Shaughnessy","Cynthia Osborne","John E Pippen","Mark Yoffe","Debra Patt","Christine Rocha","Ingrid Chou Koo","Barry M Sherman","Charles Bradley","O'Shaughnessy J","Osborne C","Pippen JE","Yoffe M","Patt D","Rocha C","Koo IC","Sherman BM","Bradley C"],"doi":"10.1056\/nejmoa1011418","issns":["1533-4406","0028-4793"],"issue":"3","journal":"New England Journal of Medicine","last_mentioned_on":1462195027,"links":["http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21208101","http:\/\/dx.doi.org\/10.1056\/NEJMoa1011418"],"pmid":"21208101","pubdate":"2011-01-20T00:00:00+00:00","publisher":"Massachusetts Medical Society","publisher_subjects":[{"name":"Medical And Health Sciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"subjects":["medicine"],"title":"Iniparib plus chemotherapy in metastatic triple-negative breast cancer.","type":"article","volume":"364","mendeley_url":"http:\/\/www.mendeley.com\/research\/iniparib-plus-chemotherapy-metastatic-triplenegative-breast-cancer-20"},"altmetric_score":{"score":37.072,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":37.072},"context_for_score":{"all":{"total_number_of_other_articles":7639268,"mean":6.5692022176954,"rank":209219,"this_scored_higher_than_pct":97,"this_scored_higher_than":7430074,"rank_type":"exact","sample_size":7639268,"percentile":97},"similar_age_3m":{"total_number_of_other_articles":7023233,"mean":6.8851423868633,"rank":204931,"this_scored_higher_than_pct":97,"this_scored_higher_than":6818298,"rank_type":"exact","sample_size":7023233,"percentile":97},"this_journal":{"total_number_of_other_articles":19119,"mean":44.724008264463,"rank":3994,"this_scored_higher_than_pct":79,"this_scored_higher_than":15124,"rank_type":"exact","sample_size":19119,"percentile":79},"similar_age_this_journal_3m":{"total_number_of_other_articles":19035,"mean":44.951676158453,"rank":3993,"this_scored_higher_than_pct":79,"this_scored_higher_than":15042,"rank_type":"exact","sample_size":19035,"percentile":79}}},"demographics":{"poster_types":{"member_of_the_public":2,"practitioner":1},"users":{"twitter":{"cohorts":{"Members of the public":2,"Practitioners (doctors, other healthcare professionals)":1}},"mendeley":{"by_status":{"Professor > Associate Professor":1,"Student  > Doctoral Student":3,"Researcher":8,"Student  > Ph. D. Student":7,"Other":3,"Student  > Master":3,"Student  > Bachelor":1,"Lecturer":1},"by_discipline":{"Engineering":1,"Materials Science":1,"Medicine and Dentistry":13,"Chemistry":1,"Agricultural and Biological Sciences":9,"Nursing and Health Professions":1,"Biochemistry, Genetics and Molecular Biology":1}}},"geo":{"twitter":{"BE":2,"NL":1},"mendeley":{"TW":1,"AU":1}}},"posts":{"blogs":[{"title":"Personalizing Diagnosis, Treatment, and Monitoring of Cancer with Genetics","url":"http:\/\/spittoon.23andme.com\/2011\/05\/12\/personalizing-diagnosis-treatment-and-monitoring-of-cancer-with-genetics\/","citation_ids":[104178],"posted_on":"2011-05-12T16:00:00+00:00","summary":"To every cancer, there is a genome &#8212; the unique DNA that determines a cancer cell. A few changes here and there to a cell&#8217;s DNA can be enough to turn a normally growing cell into one that grows and divides uncontrollably. Although we\u2019ve come a","author":{"name":"The Spittoon","url":"http:\/\/spittoon.23andme.com\/","description":"A receptacle for genetic knowledge."}},{"title":"New advances in triple negative breast cancer","url":"http:\/\/feedproxy.google.com\/~r\/PharmaStrategyBlog\/~3\/QamaPSj909M\/","license":"public","citation_ids":[104178],"posted_on":"2011-01-10T14:05:12+00:00","summary":"Iniparib phase II data in NEJM\nAt ESMO last summer the initial phase II trial data on a PARP inhibitor, iniparib (sanofi-aventis), was presented in triple negative breast cancer (TNBC).  Unfortunately, I missed that session as it clashed w","author":{"name":"Pharma Strategy Blog","url":"http:\/\/pharmastrategyblog.com\/","description":"Commentary and insights on Pharma & Biotech new product development with a focus on oncology and hematology"}}],"twitter":[{"url":"http:\/\/twitter.com\/HUMBLETIsabelle\/status\/393289276278181888","license":"public","citation_ids":[104178],"posted_on":"2013-10-24T08:14:05+00:00","author":{"name":"Isabelle HUMBLET","url":"http:\/\/www.isabellehumblet.be","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000328500057\/202433e7ef31a97093d905631713d161_normal.jpeg","description":"M\u00e9decin. Conseill\u00e8re communal d'Aywaille. M\u00e8re d'un petit gar\u00e7on. Militante de la dignit\u00e9 humaine et du respect de l'environnement.","id_on_source":"HUMBLETIsabelle","tweeter_id":"1667731981","geo":{"lt":"50.47411","ln":"5.67684","country":"BE"},"followers":219},"tweet_id":"393289276278181888"},{"url":"http:\/\/twitter.com\/#!\/aftimosp\/status\/341671859961618434","license":"public","citation_ids":[104178],"posted_on":"2013-06-03T21:44:54+00:00","author":{"name":"Philippe Aftimos, MD","url":"http:\/\/be.linkedin.com\/pub\/philippe-aftimos-md\/25\/a76\/664","image":"https:\/\/pbs.twimg.com\/profile_images\/832483544064602112\/cfYg9YGh_normal.jpg","description":"Medical Oncologist and senior research physician at @JulesBordet #Brussels. Developmental therapeutics, #BreastCancer #PrecisionMedicine. Views are my own.","id_on_source":"aftimosp","tweeter_id":"177176270","geo":{"lt":50.85045,"ln":4.34878,"country":"BE"},"followers":2412},"tweet_id":"341671859961618434"},{"url":"http:\/\/twitter.com\/cordekroon\/statuses\/341800255240679424","license":"public","citation_ids":[104178],"posted_on":"2013-06-04T06:15:05+00:00","author":{"name":"Cor de Kroon","image":"https:\/\/pbs.twimg.com\/profile_images\/781589326215905280\/KnbOS4gM_normal.jpg","description":"eerlijk \/ enthousiast \/ kritisch \/ bootje varen met vrouw en kinderen \/ gynaecoloog-oncoloog \/ Qoflife \/ chirurgische technieken","id_on_source":"cordekroon","tweeter_id":"265430464","geo":{"lt":52.5,"ln":5.75,"country":"NL"},"followers":1933},"tweet_id":"341800255240679424"}],"wikipedia":[{"title":"Iniparib","url":"http:\/\/en.wikipedia.org\/?diff=prev&oldid=407467123#altmetric_citation_2","license":"public","citation_ids":[104178],"posted_on":"2011-01-12T13:03:30+00:00","summary":"Iniparib (previously BSI 201) (4-iodo-3-nitrobenzamide) was a drug candidate for cancer treatment.","page_url":"http:\/\/en.wikipedia.org\/?curid=24370009","wiki_lang":"en","author":{"name":"Rod57","url":"http:\/\/en.wikipedia.org\/wiki\/User:Rod57"}}],"news":[{"title":"Hereditary Breast Cancer: Clinical, Pathological and Molecular Characteristics","url":"http:\/\/www.oncologynurseadvisor.com\/hereditary-breast-cancer-clinical-pathological-and-molecular-characteristics\/article\/402709\/","license":"public","citation_ids":[4034550,104178,380641,4034551,4034552,2086782,4034553,109728,4034554,4034555,914427,4034556,4034557,125800,4034558,4034559,4034560,4034561,4034563,3457255,3580801,4034564,4034565,4034566,537375,4034567,2701605,4034568,112707,3580801,2223517,189031,4034553,4034569,4034570,4034570,210436,4034571,4034572,4034573,4034550,1483253,4034574,4034575,4034576,3240131,1026570,4034577,4034578,4034579,4034581,4034583,825528,1497562,4034584,505756,4034585,4034569,3154037,4034586,4034587,1473035,4034588,3240131,4034589,210443,3065096,4034590,2086782,3264693,4034565,1492905,4034592,112707,410500,4034593,962547,4034595,4034596,508202,156026,4034575,889911,4034598,3756959,4034579,4034599,4034600,4034601,2964039,825528,4034602,147615,654504,4034599,4034559,832266,1359648,210436,2964039,4034603,4034554,2701605,4034556,4034604,4034605,3065096,4034558,4034561,4034606,4034608,3158304,1231364,1026570,4034609,4034610,4034609,4034564,165039,4034611,1497562,4034612,4034583,4034613,4034615,4034586,1479181,4034572,4034616,4034617,4034618,702996,4034619,4034620,1231364,627260,3825036,3502327,3263918,4034613,4034551,4034606,1473035,4034621,4034622,2798638,4034600,4034571,4034623,4034624,702996,1483253,4034625,3241402,508202,4034577,1479181,4034626,4034627,109728,2223517],"posted_on":"2015-03-12T13:00:00+00:00","summary":"[Breast Cancer: Basic and Clinical Research] In this review, the authors provide an overview of hereditary breast cancer, its genetic background, and clinical implications, before focusing on the pathologically and molecular features associated with the di","author":{"name":"Oncology Nurse Advisor ","url":"http:\/\/www.oncologynurseadvisor.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/276\/normal\/Screen_Shot_2014-11-20_at_11.19.42.png?1416482413"}},{"title":"Iniparib Fails to Improve Outcomes in Triple-negative Breast Cancer","url":"http:\/\/www.ascopost.com\/issues\/july-1-2011\/iniparib-fails-to-improve-outcomes-in-triple-negative-breast-cancer.aspx","license":"public","citation_ids":[104178],"posted_on":"2013-12-16T00:00:00+00:00","summary":"","author":{"name":"The ASCO Post","url":"http:\/\/www.ascopost.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/496\/normal\/Screen_Shot_2016-02-03_at_09.24.05.png?1454491455"}},{"title":"A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer","url":"http:\/\/www.oncologynurseadvisor.com\/a-review-of-systemic-treatment-in-metastatic-triple-negative-breast-cancer\/article\/493356\/","license":"public","citation_ids":[4966295,3923455,3923455,7121791,7121792,617074,617074,724678,724678,7121794,7121795,7121796,1988471,512200,7121800,7121802,7121803,1359370,3096223,7121808,210512,210512,7121812,512238,7121814,4122538,4122538,7121816,1193609,2983403,517781,3092076,3092076,7121819,7121820,7121821,7121822,7121823,7121824,7121825,7121826,868948,868948,7121828,7121829,7121830,7121832,7121834,7121836,7121837,7121841,7121842,7121843,7121844,7121846,7121847,7121848,7121849,7121850,2949152,7121851,2492718,3447625,7121855,654504,147615,7121860,193458,193458,791850,791850,432298,2607210,1871996,410500,104178,4531397,4531397,2728335,7121871,7121871,2338277,2338277,7121873,2115433,2115433,1309542,1309542,7121874,2861399,2861399,4469166,4469166,1025306,1025306,6057241,6057241,6091163,6091163,1798171,742634,7121891,2707642,2707642,7121896,3935288,2589414,2589414,1241731,2712027,750270,7121906,7121908,3914960,186456,186456,5425815,5425815,6085338,6085338],"posted_on":"2016-05-02T13:17:07+00:00","summary":"May 02, 2016 the ONA take: Approximately 246 660 patients are expected to receive a diagnosis of breast cancer in the United States in 2016.","author":{"name":"Oncology Nurse Advisor ","url":"http:\/\/www.oncologynurseadvisor.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/276\/normal\/Screen_Shot_2014-11-20_at_11.19.42.png?1416482413"}}],"f1000":[{"title":"Recommended in F1000 Prime","url":"https:\/\/f1000.com\/prime\/8186975","license":"public","citation_ids":[104178],"posted_on":"2011-02-10T00:00:00+00:00","f1000_classes":[],"f1000_score":"4"},{"title":"Recommended in F1000 Prime","url":"https:\/\/f1000.com\/prime\/8186975#1","license":"public","citation_ids":[104178],"posted_on":"2011-03-08T00:00:00+00:00","f1000_classes":[],"f1000_score":"4"}]}}